86 related articles for article (PubMed ID: 18069262)
1. [Experimental animal models of multiple myeloma].
Miyakawa Y
Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
[TBL] [Abstract][Full Text] [Related]
2. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
3. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
[TBL] [Abstract][Full Text] [Related]
4. Mouse models of human myeloma.
Mitsiades CS; Anderson KC; Carrasco DR
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1051-69, viii. PubMed ID: 17996588
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
6. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
[TBL] [Abstract][Full Text] [Related]
7. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
8. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
9. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
11. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
[TBL] [Abstract][Full Text] [Related]
12. An in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce BF; Mundy GR; Roodman GD
Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
[TBL] [Abstract][Full Text] [Related]
13. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
[TBL] [Abstract][Full Text] [Related]
14. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
15. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
16. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.
Hu Y; Wang YD; Guo T; Wei WN; Sun CY; Zhang L; Huang J
Cancer Genet Cytogenet; 2007 Oct; 178(1):1-10. PubMed ID: 17889702
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
18. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
19. The SCID-hu myeloma model.
Epstein J; Yaccoby S
Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
[TBL] [Abstract][Full Text] [Related]
20. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice.
Hjorth-Hansen H; Seifert MF; Börset M; Aarset H; Ostlie A; Sundan A; Waage A
J Bone Miner Res; 1999 Feb; 14(2):256-63. PubMed ID: 9933480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
